Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤Rani (RANI) accepted into FDA Emerging Technology Program for RaniPill platform
- ➤Cash, equivalents and marketable securities $45.3 million; runway expected through end-2027
- ➤RT-114 Phase 1a expansion cohort enrollment continues; data expected by end-2026
- ➤Q3 contract revenue $1.7 million, up from zero year over year
- ➤Q3 net loss $8.8 million versus $7.9 million year over year
Expert Statements
Talat Imran, Chief Executive Officer of Rani Therapeutics
“The third quarter marked continued progress for the RaniPill(®) platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides an opportunity to engage with the Agency on technical, manufacturing and regulatory considerations related to the RaniPill(®) platform”
Talat Imran, Chief Executive Officer of Rani Therapeutics
“We expect this engagement to be valuable as we continue to invest in manufacturing automation to support further clinical development.”
Talat Imran, Chief Executive Officer of Rani Therapeutics
“Combined with our rare disease, immunology, and obesity focused partnerships with Chugai, ProGen and PegBio, this milestone reflects our continued confidence in the RaniPill platform’s potential as an alternative to injectable biologics”
Talat Imran, Chief Executive Officer of Rani Therapeutics
“With cash, cash equivalents and marketable securities of $45.3 million, we believe we are well positioned to fund operations at least through the end of 2027 and to execute on our priorities, including additional RT-114 data by year-end.”
~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill(®) platform technology ~
~ Enrollment continues in RT-114 Phase 1a expansion cohort; data expected by end of 2026 ~
Get started
Create a free account to read the full story.